Int Heart J. 2006;47:13 20. 12. Mehta RH, Parsons L, Rao SV, et al. Association of bleeding and in-hospital mortality in black and white patients with ST-segment- elevation myocardial infarction receiving reperfusion. Circulation. 2012;125:1727 34. 13. Fox KAA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999 2006. JAMA. 2007;297: 1892 900. 14. Yeh RW, Sidney S, Chandra M, et al. Population trends in the inci- dence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155 65. 15. Mandelzweig L, Battler A, Boyko V, et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J. 2006;27:2285 93. 16. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med. 2011;124:40 7. 17. Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and out- comes of acute myocardial infarction and percutaneous coronary interven- tion. J Am Coll Cardiol. 2010;56:254 63. 18. Jernberg T, Johanson P, Held C, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myo- cardial infarction. JAMA. 2011;305:1677 84. 19. Krumholz HM, Merrill AR, Schone EM, et al. Patterns of hospi- tal performance in acute myocardial infarction and heart failure 30- day mortality and readmission. Circ Cardiovasc Qual Outcomes. 2009;2:407 13. 20. Bradley EH, Curry LA, Spatz ES, et al. Hospital strategies for reducing risk-standardized mortality rates in acute myocardial infarction. Ann In- tern Med. 2012;156:618 26. 21. Gharacholou SM, Alexander KP, Chen AY, et al. Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment el- evation myocardial infarction: findings from the CRUSADE initiative. Am Heart J. 2010;159:757 63. 22. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleed- ing in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress AD- verse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119:1873 82. O Gara et al 2013 ACCF/AHA STEMI Guideline e403 23. Glickman SW, Granger CB, Ou F-S, et al. Impact of a statewide ST-seg- ment-elevation myocardial infarction regionalization program on treat- ment times for women, minorities, and the elderly. Circ Cardiovasc Qual Outcomes. 2010;3:514 21. 24. Wynia MK, Ivey SL, Hasnain-Wynia R. Collection of data on patients race and ethnic group by physician practices. N Engl J Med. 2010;362:846 50. 25. Grundy SM, Garber A, Goldberg R, et al. Prevention Conference VI: Dia- betes and Cardiovascular Disease: Writing Group IV: lifestyle and medi- cal management of risk factors. Circulation. 2002;105:e153 8. 26. Eckel RH, Kahn R, Robertson RM, et al. Preventing cardiovascular dis- ease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006;113:2943 6. 27. Rasoul S, Ottervanger JP, de Boer M-J, et al. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST- elevation myocardial infarction. Coron Artery Dis. 2009;20:415 21. 28. De Luca G, Gibson CM, Bellandi F, et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mor- tality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atheroscle- rosis. 2009;207:181 5. 29. Svensson A-M, McGuire DK, Abrahamsson P, et al. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26:1255 61. 30. Worthley MI, Shrive FM, Anderson TJ, et al. Prognostic implication of hyperglycemia in myocardial infarction and primary angioplasty. Am J Med. 2007;120:643 7.e1 7. 31. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and in- creased risk of death after myocardial infarction in patients with and with- out diabetes: a systematic overview. Lancet. 2000;355:773 8. 32. Timmer JR, van der Horst ICC, Ottervanger JP, et al. Prognostic value of admission glucose in non-diabetic patients with myocardial infarction. Am Heart J. 2004;148:399 404. 33. Ishihara M, Kagawa E, Inoue I, et al. Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol. 2007;99:1674 9. 34. Porter A, Assali AR, Zahalka A, et al. Impaired fasting glucose and out- comes of ST-elevation acute coronary syndrome treated with primary per- cutaneous intervention among patients without previously known diabetes mellitus. Am Heart J. 2008;155:284 9. 35. Marso SP, Miller T, Rutherford BD, et al. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary interven- tion in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol. 2007;100:206 10. 36. Timmer JR, van der Horst ICC, de Luca G, et al. Comparison of myocar- dial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol. 2005;95:1375 7. 37. Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scien- tific statement for healthcare professionals from the American Heart Asso- ciation Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115:2570 89. 38. Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the So- ciety of Geriatric Cardiology. Circulation. 2007;115:2549 69. 39. Michaels AD, Spinler SA, Leeper B, et al. Medication errors in acute car- diovascular and stroke patients: a scientific statement from the American Heart Association. Circulation. 2010;121:1664 82. 40. Shah P, Najafi AH, Panza JA, et al. Outcomes and quality of life in patients > or =85 years of age with ST-elevation myocardial infarction. Am J Car- diol. 2009;103:170 4. 41. Lewis WR, Ellrodt AG, Peterson E, et al. Trends in the use of evidence- based treatments for coronary artery disease among women and the el- derly: findings from the Get With The Guidelines Quality-Improvement Program. Circ Cardiovasc Qual Outcomes. 2009;2:633 41. 42. Herzog CA. Acute myocardial infarction in patients with end-stage renal disease. Kidney Int Suppl. 1999;71:S130 3. 43. Reddan DN, Szczech L, Bhapkar MV, et al. Renal function, concomi- tant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant. 2005;20:2105 12. 44. Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal in- sufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137:555 62. 45. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angio- tensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201 8. 46. Medi C, Montalescot G, Budaj A, et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). JACC Cardiovasc Interv. 2009;2:26 33. 47. Tsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA. 2009;302:2458 64. 48. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myo- cardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909 45. 49. Mehta RH, Califf RM, Garg J, et al. The impact of anthropomorphic in- dices on clinical outcomes in patients with acute ST-elevation myocardial infarction. Eur Heart J. 2007;28:415 24. 50. Goldberg RJ, Spencer FA, Fox KAA, et al. Prehospital delay in patients with acute coronary syndromes (from the Global Registry of Acute Coro- nary Events [GRACE]). Am J Cardiol. 2009;103:598 603. 51. Spencer FA, Montalescot G, Fox KAA, et al. Delay to reperfusion in pa- tients with acute myocardial infarction presenting to acute care hospitals: an international perspective. Eur Heart J. 2010;31:1328 36. 52. Goff DC Jr, Feldman HA, McGovern PG, et al; Rapid Early Action for Coronary Treatment (REACT) Study Group. Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial. Am Heart J. 1999;138:1046 57. 53. Goldberg RJ, Steg PG, Sadiq I, et al. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am J Cardiol. 2002;89:791 6. 54. Finnegan JR Jr, Meischke H, Zapka JG, et al. Patient delay in seeking care for heart attack symptoms: findings from focus groups conducted in five U.S. regions. Prev Med. 2000;31:205 13. 55. McKinley S, Moser DK, Dracup K. Treatment-seeking behavior for acute myocardial infarction symptoms in North America and Australia. Heart Lung. 2000;29:237 47. 56. Feldman HA, Proschan MA, Murray DM, et al. Statistical design of RE- ACT (Rapid EarlyAction for Coronary Treatment), a multisite community trial with continual data collection. Control Clin Trials. 1998;19:391 403. 57. Leslie WS, Urie A, Hooper J, et al. Delay in calling for help during myo- cardial infarction: reasons for the delay and subsequent pattern of access- ing care. Heart. 2000;84:137 41. 58. Rucker D, Brennan T, Burstin H. Delay in seeking emergency care. Acad Emerg Med. 2001;8:163 9. 59. Wenger NK.You ve come a long way, baby: cardiovascular health and dis- ease in women: problems and prospects. Circulation. 2004;109:558 60. 60. Dracup K, Alonzo AA, Atkins JM, et al; Working Group on Educational Strategies to Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. The physician s role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommen- dations from the National Heart Attack Alert Program. Ann Intern Med. 1997;126:645 51. 61. Alonzo AA. The impact of the family and lay others on care-seeking dur- ing life-threatening episodes of suspected coronary artery disease. Soc Sci Med. 1986;22:1297 311. 62. Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community in- tervention on patient delay and emergency medical service use in acute coronary heart disease: the Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA. 2000;284:60 7. 63. National Emergency Number Association. Available at: http://www.nena. org. Accessed July 26, 2012. 64. Mathews R, Peterson ED, Li S, et al. Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarc- tion: findings from the National Cardiovascular Data Registry Acute Cor- onary Treatment Intervention Outcomes Network Registry-Get With The Guidelines. Circulation. 2011;124:154 63. 65. Brown AL, Mann NC, Daya M, et al. Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients: Rapid Early Action for Coronary Treatment (REACT) study. Circulation. 2000;102:173 8. 66. Canto JG, Zalenski RJ, Ornato JP, et al. Use of emergency medical servic- es in acute myocardial infarction and subsequent quality of care: observa- tions from the National Registry of Myocardial Infarction 2. Circulation. 2002;106:3018 23. 67. Becker L, Larsen MP, Eisenberg MS. Incidence of cardiac arrest during self-transport for chest pain. Ann Emerg Med. 1996;28:612 6. 68. Hutchings CB, Mann NC, Daya M, et al. Patients with chest pain calling 9-1-1 or self-transporting to reach definitive care: which mode is quicker? Am Heart J. 2004;147:35 41. 69. Ting HH, Krumholz HM, Bradley EH, et al. Implementation and in- tegration of prehospital ECGs into systems of care for acute coronary syndrome: a scientific statement from the American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research, Emergency Cardiovascular Care Committee, Council on Cardio- vascular Nursing, and Council on Clinical Cardiology. Circulation. 2008;118:1066 79. 70. S rensen JT, Terkelsen CJ, N rgaard BL, et al. Urban and rural implemen- tation of pre-hospital diagnosis and direct referral for primary percutane- ous coronary intervention in patients with acute ST-elevation myocardial infarction. Eur Heart J. 2011;32:430 6. 71. Le May MR, So DY, Dionne R, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2008;358:231 40. 72. Rokos IC, French WJ, Koenig WJ, et al. Integration of pre-hospital elec- trocardiograms and ST-elevation myocardial infarction receiving center (SRC) networks: impact on door-to-balloon times across 10 independent regions. JACC Cardiovasc Interv. 2009;2:339 46. 73. Faxon D, Lenfant C. Timing is everything: motivating patients to call 9-1- 1 at onset of acute myocardial infarction. Circulation. 2001;104:1210 1. 74. National Institutes of Health, US Department of Health and Human Ser- vices.Act in Time. National Heart, Lung, and Blood Institute.Available at: http://health.nih.gov/topic/HeartAttack/. Accessed July 26, 2012. 75. McDermott MM, Mandapat AL, Moates A, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coro- nary or peripheral arterial disease. Arch Intern Med. 2003;163:2157 62. 76. Aguirre FV, Varghese JJ, Kelley MP, et al. Rural interhospital trans- fer of ST-elevation myocardial infarction patients for percutane- ous coronary revascularization: the Stat Heart Program. Circulation. 2008;117:1145 52. 77. Henry TD, Sharkey SW, Burke MN, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation. 2007;116:721 8. 78. Jollis JG, Roettig ML, Aluko AO, et al. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial in- farction. JAMA. 2007;298:2371 80. 79. Dieker H-J, Liem SSB, El Aidi H, et al. Pre-hospital triage for primary angioplasty: direct referral to the intervention center versus interhospital transport. JACC Cardiovasc Interv. 2010;3:705 11. 80. Diercks DB, Kontos MC, Chen AY, et al. Utilization and impact of pre- hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. J Am Coll Cardiol. 2009;53:161 6. 81. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collab- orative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311 22. Erratum in: Lancet. 1994;343:742. 82. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative re- view of 23 randomised trials. Lancet. 2003;361:13 20. 83. Andersen HR, Nielsen TT, Vesterlund T, et al. Danish multicenter random- ized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2). Am Heart J. 2003;146: 234 41. 84. Dalby M, Bouzamondo A, Lechat P, et al. Transfer for primary angio- plasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108:1809 14. 85. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733 42. 86. Nielsen PH, Terkelsen CJ, Nielsen TT, et al. System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myo- cardial Infarction-2 [DANAMI-2] trial). Am J Cardiol. 2011;108:776 81. 87. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) ev- erything? Am J Cardiol. 2003;92:824 6. 88. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfu- sion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006;114:2019 25. 89. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996; 348:771 5. 90. Chareonthaitawee P, Gibbons RJ, Roberts RS, et al; for the CORE in- vestigators (Collaborative Organisation for RheothRx Evaluation). The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. Heart. 2000;84:142 8. 91. McNamara RL, Herrin J, Wang Y, et al. Impact of delay in door-to-nee- dle time on mortality in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2007;100:1227 32. 92. Milavetz JJ, Giebel DW, Christian TF, et al. Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol. 1998;31:1246 51. 93. Newby LK, Rutsch WR, Califf RM, et al; GUSTO-1 Investigators. Time from symptom onset to treatment and outcomes after thrombolytic ther- apy. J Am Coll Cardiol. 1996;27:1646 55. 94. Sch mig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293:2865 72. 95. Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary per- cutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PL-ACS]). Am J Car- diol. 2011;107:501 8. 96. Rathore SS, Curtis JP, Chen J, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocar- dial infarction: national cohort study. BMJ. 2009;338:b1807. 97. Terkelsen CJ, Jensen LO, Tilsted H-H, et al. Health care system de- lay and heart failure in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: follow-up of population-based medical registry data. Ann Intern Med. 2011;155:361 7. 98. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treat- ment and mortality in primary angioplasty for acute myocardial infarc- tion: every minute of delay counts. Circulation. 2004;109:1223 5. 99. Terkelsen CJ, S rensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coro- nary intervention. JAMA. 2010;304:763 71. 100. Pinto DS, Frederick PD, Chakrabarti AK, et al. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrino- lytic declines as delays increase. Circulation. 2011;124:2512 21. 101. Armstrong PW, Boden WE. Reperfusion paradox in ST-segment eleva- tion myocardial infarction. Ann Intern Med. 2011;155:389 91. 102. Bates ER, Nallamothu BK. Commentary: the role of percutaneous coro- nary intervention in ST-segment-elevation myocardial infarction. Circu- lation. 2008;118:567 73. 103. Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J. 2004;147:E16. O Gara et al 2013 ACCF/AHA STEMI Guideline e405 104. Krumholz HM, Bradley EH, Nallamothu BK, et al. A campaign to im- prove the timeliness of primary percutaneous coronary intervention: Door-to-Balloon: An Alliance for Quality. JACC Cardiovasc Interv. 2008;1:97 104. 105. Bradley EH, Nallamothu BK, Stern AF, et al. The Door-to-Balloon Alliance for Quality: who joins national collaborative efforts and why? Jt Comm J Qual Patient Saf. 2009;35:93 9. 106. Jacobs AK, Antman EM, Faxon DP, et al. Development of systems of care for ST-elevation myocardial infarction patients: executive summary. Circulation. 2007;116:217 30. Erratum in: Circulation. 2007;116:e77. 107. Antman EM. Time is muscle: translation into practice. J Am Coll Car- diol. 2008;52:1216 21. 108. Kontos MC, Kurz MC, Roberts CS, et al. An evaluation of the accuracy of emergency physician activation of the cardiac catheterization labora- tory for patients with suspected ST-segment elevation myocardial infarc- tion. Ann Emerg Med. 2010;55:423 30. 109. Lee CH, Van Gelder CM, Cone DC. Early cardiac catheterization labo- ratory activation by paramedics for patients with ST-segment elevation myocardial infarction on prehospital 12-lead electrocardiograms. Pre- hosp Emerg Care. 2010;14:153 8. 110. Trivedi K, Schuur JD, Cone DC. Can paramedics read ST-segment eleva- tion myocardial infarction on prehospital 12-lead electrocardiograms? Prehosp Emerg Care. 2009;13:207 14. 111. Willson AB, Mountain D, Jeffers JM, et al. Door-to-balloon times are reduced in ST-elevation myocardial infarction by emergency physician activation of the cardiac catheterisation laboratory and immediate patient transfer. Med J Aust. 2010;193:207 12. 112. Youngquist ST, Shah AP, Niemann JT, et al. A comparison of door-to- balloon times and false-positive activations between emergency depart- ment and out-of-hospital activation of the coronary catheterization team. Acad Emerg Med. 2008;15:784 7. 113. Larson DM, Menssen KM, Sharkey SW, et al. False-positive cardiac catheterization laboratory activation among patients with suspected ST- segment elevation myocardial infarction. JAMA. 2007;298:2754 60. 114. Garvey JL, Monk L, Granger CB, et al. Rates of cardiac catheterization cancelation for ST-segment elevation myocardial infarction after activa- tion by emergency medical services or emergency physicians: results from the North Carolina Catheterization Laboratory Activation Registry. Circulation. 2012;125:308 13. 115. Rokos IC, French WJ, Mattu A, et al. Appropriate cardiac cath lab ac- tivation: optimizing electrocardiogram interpretation and clinical deci- sion-making for acute ST-elevation myocardial infarction. Am Heart J. 2010;160:995 1003, 1003.e1 8. 116. Mixon TA, Suhr E, Caldwell G, et al. Retrospective description and anal- ysis of consecutive catheterization laboratory ST-segment elevation myo- cardial infarction activations with proposal, rationale, and use of a new classification scheme. Circ Cardiovasc Qual Outcomes. 2012;5:62 9. 117. Jacobs AK. Primary percutaneous coronary intervention without cardiac surgery on-site: coming to a hospital near you? Am Heart J. 2008;155: 585 8. 118. Jollis JG, Mehta RH, Roettig ML, et al. Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study de- sign. Am Heart J. 2006;152:851.e1 11. 119. Kalla K, Christ G, Karnik R, et al. Implementation of guidelines im- proves the standard of care: the Viennese registry on reperfusion strat- egies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation. 2006;113:2398 405. 120. Rokos IC, Larson DM, Henry TD, et al. Rationale for establishing re- gional ST-elevation myocardial infarction receiving center (SRC) net- works. Am Heart J. 2006;152:661 7. 121. Ting HH, Rihal CS, Gersh BJ, et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation. 2007;116:729 36. 122. American Heart Association. Mission Lifeline. Available at: http://www. heart.org/HEARTORG/HealthcareResearch/MissionLifelineHomePage/ cessed July 26, 2012. 123. Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplas- ty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J. 2009;30:1598 606. 124. Bradley EH, Curry LA, Ramanadhan S, et al. Research in action: us- ing positive deviance to improve quality of health care. Implement Sci. 2009;4:25. 125. Widimsk P, Budes nsk T, Vor c D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial: PRAGUE-2. Eur Heart J. 2003;24:94 104. 126. Chakrabarti A, Krumholz HM, Wang Y, et al. Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. J Am Coll Cardiol. 2008;51:2442 3. 127. Wang TY, Peterson ED, Ou F-S, et al. Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. Am Heart J. 2011;161:76 83.e1. 128. Miedema MD, Newell MC, Duval S, et al. Causes of delay and associ- ated mortality in patients transferred with ST-segment-elevation myocar- dial infarction. Circulation. 2011;124:1636 44. 129. Wang TY, Nallamothu BK, Krumholz HM, et al. Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. JAMA. 2011;305:2540 7. 130. Primary versus tenecteplase-facilitated percutaneous coronary interven- tion in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569 78. 131. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205 17. 132. Bradley EH, Herrin J, Wang Y, et al. Door-to-drug and door-to-balloon times: where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI). Am Heart J. 2006;151:1281 7. 133. Jacobs AK, Antman EM, Ellrodt G, et al. Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. Circulation. 2006;113:2152 63. 134. McNamara RL, Herrin J, Bradley EH, et al. Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J Am Coll Cardiol. 2006;47:45 51. 135. Bradley EH, Curry LA, Webster TR, et al. Achieving rapid door-to-bal- loon times: how top hospitals improve complex clinical systems. Circula- tion. 2006;113:1079 85. 136. Bradley EH, Nallamothu BK, Herrin J, et al. National efforts to improve door-to-balloon time results from the Door-to-Balloon Alliance. J Am Coll Cardiol. 2009;54:2423 9. 137. Nestler DM, Noheria A, Haro LH, et al. Sustaining improvement in door- to-balloon time over 4 years: the Mayo Clinic ST-elevation myocardial infarction protocol. Circ Cardiovasc Qual Outcomes. 2009;2:508 13. 138. Pitta SR, Myers LA, Bjerke CM, et al. Using prehospital electrocar- diograms to improve door-to-balloon time for transferred patients with ST-elevation myocardial infarction: a case of extreme performance. Circ Cardiovasc Qual Outcomes. 2010;3:93 7. 139. Daudelin DH, Sayah AJ, Kwong M, et al. Improving use of prehospi- tal 12-lead ECG for early identification and treatment of acute coronary syndrome and ST-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2010;3:316 23. 140. Curtis JP, Herrin J, Bratzler DW, et al. Trends in race-based differences in door-to-balloon times. Arch Intern Med. 2010;170:992 3. 141. Krumholz HM, Herrin J, Miller LE, et al. Improvements in door-to- balloon time in the United States, 2005 to 2010. Circulation. 2011;124: 1038 45. 142. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty ver- sus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet. 2002;360:825 9. 143. Castaigne AD, Herv C, Duval-Moulin AM, et al. Prehospital use of AP- SAC: results of a placebo-controlled study. Am J Cardiol. 1989;64:30A- -33A; discussion 41A 42A. 144. Danchin N, Blanchard D, Steg PG, et al. Impact of prehospital thrombol- ysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation. 2004;110:1909 15. 145. The European Myocardial Infarction Project Group. Prehospital throm- bolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med. 1993;329:383 9. 146. Roth A, Barbash GI, Hod H, et al. Should thrombolytic therapy be ad- ministered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study. J Am Coll Cardiol. 1990;15:932 6. 147. Schofer J, B ttner J, Geng G, et al. Prehospital thrombolysis in acute myocardial infarction. Am J Cardiol. 1990;66:1429 33. 148. Bj rklund E, Stenestrand U, Lindb ck J, et al. Pre-hospital thromboly- sis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J. 2006;27:1146 52. 149. Morrow DA, Antman EM, Sayah A, et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol. 2002;40:71 7. 150. Pedley DK, Bissett K, Connolly EM, et al. Prospective observational co- hort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics. BMJ. 2003;327:22 6. 151. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. JAMA. 1993;270:1211 6. 152. Welsh RC, Travers A, Senaratne M, et al. Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center. Am Heart J. 2006;152:1007 14. 153. GREAT Group. Feasibility, safety, and efficacy of domiciliary thrombol- ysis by general practitioners: Grampian region Early Anistreplase Trial. BMJ. 1992;305:548 53. 154. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA. 2000;283:2686 92. 155. Westerhout CM, Bonnefoy E, Welsh RC, et al. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST- elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAP- TIM and WEST. Am Heart J. 2011;161:283 90. 156. Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: post-cardiac ar- rest care: 2010 American Heart Association Guidelines for Cardiopul- monary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122:S768 86. Errata in: Circulation. 2011;124:e403 and Circula- tion. 2011;123:e237. 157. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survi- vors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557 63. 158. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549 56. Erratum in: N Engl J Med. 2002;346:1756. 159. Nichol G, Aufderheide TP, Eigel B, et al. Regional systems of care for out-of-hospital cardiac arrest: a policy statement from the American Heart Association. Circulation. 2010;121:709 29. Erratum in: Circula- tion. 2010;122:e439. 160. Bendz B, Eritsland J, Nakstad AR, et al. Long-term prognosis after out- of-hospital cardiac arrest and primary percutaneous coronary interven- tion. Resuscitation. 2004;63:49 53. 161. Borger van der Burg AE, Bax JJ, Boersma E, et al. Impact of percuta- neous coronary intervention or coronary artery bypass grafting on out- come after nonfatal cardiac arrest outside the hospital. Am J Cardiol. 2003;91:785 9. 162. Bulut S, Aengevaeren WR, Luijten HJ, et al. Successful out-of-hospital cardiopulmonary resuscitation: what is the optimal in-hospital treatment strategy? Resuscitation. 2000;47:155 61. 163. Garot P, Lefevre T, Eltchaninoff H, et al. Six-month outcome of emer- gency percutaneous coronary intervention in resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction. Circula- tion. 2007;115:1354 62. 164. Gorjup V, Radsel P, Kocjancic ST, et al. Acute ST-elevation myocardial infarction after successful cardiopulmonary resuscitation. Resuscitation. 2007;72:379 85. 165. Hosmane VR, Mustafa NG, Reddy VK, et al. Survival and neurologic recovery in patients with ST-segment elevation myocardial infarction re- suscitated from cardiac arrest. J Am Coll Cardiol. 2009;53:409 15. 166. Kahn JK, Glazier S, Swor R, et al. Primary coronary angioplasty for acute myocardial infarction complicated by out-of-hospital cardiac ar- rest. Am J Cardiol. 1995;75:1069 70. 167. Keelan PC, Bunch TJ, White RD, et al. Early direct coronary angio- plasty in survivors of out-of-hospital cardiac arrest. Am J Cardiol. 2003;91:1461 3, A6. 168. Kern KB, Rahman O. Emergent percutaneous coronary intervention for resuscitated victims of out-of-hospital cardiac arrest. Catheter Cardio- vasc Interv. 2010;75:616 24. 169. Marcusohn E, Markusohn E, Roguin A, et al. Primary percutaneous coro- nary intervention after out-of-hospital cardiac arrest: patients and out- comes. Isr Med Assoc J. 2007;9:257 9. 170. Pleskot M, Babu A, Hazukova R, et al. Out-of-hospital cardiac ar- rests in patients with acute ST elevation myocardial infarctions in the East Bohemian region over the period 2002 2004. Cardiology. 2008;109:41 51. 171. Quintero-Moran B, Moreno R, Villarreal S, et al. Percutaneous coronary intervention for cardiac arrest secondary to ST-elevation acute myocar- dial infarction: influence of immediate paramedical/medical assistance on clinical outcome. J Invasive Cardiol. 2006;18:269 72. 172. Richling N, Herkner H, Holzer M, et al. Thrombolytic therapy vs primary percutaneous intervention after ventricular fibrillation cardiac arrest due to acute ST-segment elevation myocardial infarction and its effect on out- come. Am J Emerg Med. 2007;25:545 50. 173. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary an- giography in survivors of out-of-hospital cardiac arrest. N Engl J Med. 1997;336:1629 33. 174. Werling M, Thor n A-B, Axelsson C, et al. Treatment and outcome in post-resuscitation care after out-of-hospital cardiac arrest when a modern therapeutic approach was introduced. Resuscitation. 2007;73:40 5. 175. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46 215. Errata in: Circulation. 2011;124:e425 and Circulation. 2010;121:e260. 176. Nichol G, Thomas E, Callaway CW, et al. Regional variation in out-of- hospital cardiac arrest incidence and outcome. JAMA. 2008;300:1423 31. Erratum in: JAMA. 2008;300:1763. 177. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol. 2004;44:1268 75. 178. Valenzuela TD, Roe DJ, Cretin S, et al. Estimating effectiveness of cardi- ac arrest interventions: a logistic regression survival model. Circulation. 1997;96:3308 13. 179. Cummins RO, Ornato JP, Thies WH, et al. Improving survival from sud- den cardiac arrest: the chain of survival concept: a statement for health professionals from the Advanced Cardiac Life Support Subcommittee and the Emergency Cardiac Care Committee, American Heart Associa- tion. Circulation. 1991;83:1832 47. 180. Larsen MP, Eisenberg MS, Cummins RO, et al. Predicting survival from out-of-hospital cardiac arrest: a graphic model. Ann Emerg Med. 1993;22:1652 8. 181. Weisfeldt ML, Sitlani CM, Ornato JP, et al. Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the Resuscitation Outcomes Consortium popula- tion of 21 million. J Am Coll Cardiol. 2010;55:1713 20. 182. White RD, Hankins DG, Bugliosi TF. Seven years experience with early defibrillation by police and paramedics in an emergency medical services system. Resuscitation. 1998;39:145 51. 183. Hallstrom AP, Ornato JP, Weisfeldt M, et al. Public-access defibril- lation and survival after out-of-hospital cardiac arrest. N Engl J Med. 2004;351:637 46. 184. Mosesso VN Jr, Newman MM, Ornato JP, et al. Law Enforcement Agency Defibrillation (LEA-D): proceedings of the National Center for Early Defibrillation Police AED Issues Forum. Prehosp Emerg Care. 2002;6:273 82. 185. Groh WJ, Lowe MR, Overgaard AD, et al. Attitudes of law enforcement officers regarding automated external defibrillators. Acad Emerg Med. 2002;9:751 3. 186. Koster RW. Automatic external defibrillator: key link in the chain of sur- vival. J Cardiovasc Electrophysiol. 2002;13:S92 5. 187. Myerburg RJ, Fenster J, Velez M, et al. Impact of community-wide police car deployment of automated external defibrillators on survival from out- of-hospital cardiac arrest. Circulation. 2002;106:1058 64. 188. Ornato JP, McBurnie MA, Nichol G, et al. The Public Access Defibril- lation (PAD) trial: study design and rationale. Resuscitation. 2003;56: 135 47. O Gara et al 2013 ACCF/AHA STEMI Guideline e407 189. Caffrey SL, Willoughby PJ, Pepe PE, et al. Public use of automated ex- ternal defibrillators. N Engl J Med. 2002;347:1242 7. 190. Donaldson E, Pearn J. First aid in the air.Aust NZ J Surg. 1996;66:431 4. 191. Page RL, Joglar JA, Kowal RC, et al. Use of automated external defibril- lators by a U.S. airline. N Engl J Med. 2000;343:1210 6. 192. Valenzuela TD, Roe DJ, Nichol G, et al. Outcomes of rapid defibrilla- tion by security officers after cardiac arrest in casinos. N Engl J Med. 2000;343:1206 9. 193. Karch SB, Graff J, Young S, et al. Response times and outcomes for car- diac arrests in Las Vegas casinos. Am J Emerg Med. 1998;16:249 53. 194. Belliard G, Catez E, Charron C, et al. Efficacy of therapeutic hypother- mia after out-of-hospital cardiac arrest due to ventricular fibrillation. Re- suscitation. 2007;75:252 9. 195. Castrej n S, Cort s M, Salto ML, et al. Improved prognosis after us- ing mild hypothermia to treat cardiorespiratory arrest due to a cardi- ac cause: comparison with a control group. Rev Esp Cardiol. 2009; 62:733 41. 196. Ornato JP, Peberdy MA, Tadler SC, et al. Factors associated with the occurrence of cardiac arrest during hospitalization for acute myocardial infarction in the second national registry of myocardial infarction in the US. Resuscitation. 2001;48:117 23. 197. Lettieri C, Savonitto S, De Servi S, et al. Emergency percutaneous coro- nary intervention in patients with ST-elevation myocardial infarction complicated by out-of-hospital cardiac arrest: early and medium-term outcome. Am Heart J. 2009;157:569 75.e1. 198. Reynolds JC, Callaway CW, El Khoudary SR, et al. Coronary angiog- raphy predicts improved outcome following cardiac arrest: propensity- adjusted analysis. J Intensive Care Med. 2009;24:179 86. 199. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310:1137 40. 200. Bangalore S, Hochman JS. A routine invasive strategy for out-of-hos- pital cardiac arrest survivors: are we there yet? Circ Cardiovasc Interv. 2010;3:197 9. 201. Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Re- suscitation and Emergency Cardiovascular Care. Circulation. 2010;122: S640 56. 202. Nolan JP, Soar J. Post resuscitation care: time for a care bundle? Resus- citation. 2008;76:161 2. 203. Sunde K, Pytte M, Jacobsen D, et al. Implementation of a standardised treatment protocol for post resuscitation care after out-of-hospital cardiac arrest. Resuscitation. 2007;73:29 39. 204. McMullan PW Jr, White CJ. Doing what s right for the resuscitated. Catheter Cardiovasc Interv. 2010;76:161 3. 205. Holmes DR, Selzer F, Johnston JM, et al. Modeling and risk prediction in the current era of interventional cardiology: a report from the Na- tional Heart, Lung, and Blood Institute Dynamic Registry. Circulation. 2003;107:1871 6. 206. Matheny ME, Ohno-Machado L, Resnic FS. Discrimination and cali- bration of mortality risk prediction models in interventional cardiology. J Biomed Inform. 2005;38:367 75. 207. Resnic FS, Normand S-LT, Piemonte TC, et al. Improvement in mortality risk prediction after percutaneous coronary intervention through the ad- dition of a compassionate use variable to the National Cardiovascular Data Registry CathPCI Dataset: a study from the Massachusetts Angio- plasty Registry. J Am Coll Cardiol. 2011;57:904 11. 208. Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999;341:1413 9. 209. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Inves- tigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621 8. Erratum in: N Engl J Med. 1997;337:287. 210. Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of im- mediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA. 2003;290:1891 8. 211. Zahn R, Schuster S, Schiele R, et al; Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy. Catheter Cardiovasc Interv. 1999;46:127 33. 212. Hochman JS, Sleeper LA, Webb JG, et al; for the SHOCK Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341:625 34. 213. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395 407. 214. Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation. 2005;112:2017 21. 215. Wu AH, Parsons L, Every NR, et al. Hospital outcomes in patients pre- senting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002;40:1389 94. 216. Hannan EL, Samadashvili Z, Walford G, et al. Culprit vessel percu- taneous coronary intervention versus multivessel and staged percu- taneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv. 2010;3:22 31. 217. Toma M, Buller CE, Westerhout CM, et al. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J. 2010;31:1701 7. 218. Vlaar PJ, Mahmoud KD, Holmes DR Jr, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multives- sel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol. 2011;58:692 703. 219. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the Ameri- can College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiog- raphy and Interventions. Circulation. 2011;124:e574 e651. 220. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281 92. 221. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915 20. 222. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358: 557 67. 223. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial in- farction: the INFUSE-AMI randomized trial. JAMA. 2012;307:1817 26. 224. Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of staged versus one-time multivessel percutaneous intervention in acute myo- cardial infarction: analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial In- farction) trial. J Am Coll Cardiol. 2011;58:704 11. 225. Qarawani D, Nahir M, Abboud M, et al. Culprit only versus com- plete coronary revascularization during primary PCI. Int J Cardiol. 2008;123:288 92. 226. Khattab AA, Abdel-Wahab M, R ther C, et al. Multi-vessel stenting dur- ing primary percutaneous coronary intervention for acute myocardial infarction: a single-center experience. Clin Res Cardiol. 2008;97:32 8. 227. Varani E, Balducelli M, Aquilina M, et al. Single or multivessel percu- taneous coronary intervention in ST-elevation myocardial infarction pa- tients. Catheter Cardiovasc Interv. 2008;72:927 33. 228. Navarese EP, De Servi S, Buffon A, et al. Clinical impact of simultane- ous complete revascularization vs. culprit only primary angioplasty in patients with ST-elevation myocardial infarction and multivessel disease: a meta-analysis. J Thromb Thrombolysis. 2011;31:217 25. 229. Bangalore S, Kumar S, Poddar KL, et al. Meta-analysis of multivessel coronary artery revascularization versus culprit-only revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. Am J Cardiol. 2011;107:1300 10. 230. Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coro- nary plaques in patients with acute myocardial infarction. N Engl J Med. 2000;343:915 22. 231. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombo- sis leading to infarction and/or sudden death: autopsy evidence of recur- rent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985;71:699 708. 232. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007;297:1985 91. 233. Madsen JK, Grande P, Saunam ki K, et al. Danish multicenter random- ized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI): DANish trial in Acute Myocardial Infarction. Circulation. 1997;96:748 55. 234. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a com- prehensive meta-analysis of randomized trials. Eur Heart J. 2008;29: 2989 3001. 235. Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (Thrombectomy With Export Catheter in Infarct-Related Artery During Primary Percutaneous Coronary Intervention) prospective, randomized trial. J Am Coll Cardiol. 2009;53:309 15. 236. Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial in- farction: 30-day results from a multicenter randomized study. J Am Coll Cardiol. 2006;48:244 52. 237. Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction: the JET- STENT trial. J Am Coll Cardiol. 2010;56:1298 306. 238. Nordmann AJ, Hengstler P, Harr T, et al. Clinical outcomes of prima- ry stenting versus balloon angioplasty in patients with myocardial in- farction: a meta-analysis of randomized controlled trials. Am J Med. 2004;116:253 62. 239. Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta- analysis of randomized clinical trials. Am J Cardiol. 2001;88:297 301. 240. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circu- lation. 2006;113:2803 9. 241. Ka uza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of non- cardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35:1288 94. 242. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature dis- continuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, Ameri- can College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental As- sociation, with representation from the American College of Physicians. Circulation. 2007;115:813 8. 243. Park D-W, Park S-W, Park K-H, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352 6. 244. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004;109:1930 2. 245. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584 91. 246. Nasser M, Kapeliovich M, Markiewicz W. Late thrombosis of sirolimus- eluting stents following noncardiac surgery. Catheter Cardiovasc Interv. 2005;65:516 9. 247. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28:2706 13. 248. Stone GW,Witzenbichler B, Guagliumi G, et al. Bivalirudin during prima- ry PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218 30. 249. R ber L, Wohlwend L, Wigger M, et al. Five-year clinical and angio- graphic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitax- el-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819 28. 250. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive net- work meta-analysis. Lancet. 2012;379:1393 402. 251. Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J. 2009;30:900 7. 252. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation. 1987;76:125 34. 253. Mehta SR, Bassand J-P, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930 42. Erratum in: N Engl J Med. 2010;363:1585. 254. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71 86. Erratum in: BMJ. 2002;324:141. 255. Sch mig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary- artery stents. N Engl J Med. 1996;334:1084 9. 256. Deleted in press. 257. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foun- dation. Circulation. 2011;124: 2458 73. 258. Patti G, B rczi G, Orlic D, et al. Outcome comparison of 600- and 300- mg loading doses of clopidogrel in patients undergoing primary per- cutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial In- farction) randomized study. J Am Coll Cardiol. 2011;58:1592 9. 259. Mehta SR, Tanguay J-F, Eikelboom JW, et al. Double-dose versus stan- dard-dose clopidogrel and high-dose versus low-dose aspirin in individu- als undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233 43. 260. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001 15. 261. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circu- lation. 2010;122:2131 41. 262. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double- blind, randomised controlled trial. Lancet. 2009;373:723 31. 263. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 pa- tients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005; 95:1218 22. 264. Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardio- vascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379 86. 265. Brener SJ, Barr LA, Burchenal JE, et al; for the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Cir- culation. 1998;98:734 41. 266. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957 66. 267. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/ IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895 903. 268. ten Berg JM, van t Hof AWJ, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment el- evation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol. 2010;55:2446 55. 269. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolim- us-eluting or uncoated stents for acute myocardial infarction: the MUL- TISTRATEGY randomized trial. JAMA. 2008;299:1788 99. 270. Akerblom A, James SK, Koutouzis M, et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol. 2010;56:470 5. O Gara et al 2013 ACCF/AHA STEMI Guideline e409 271. Ellis SG, Tendera M, de Belder MA, et al. 1-Year survival in a random- ized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv. 2009;2:909 16. 272. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary in- tervention of acute ST-segment elevation myocardial infarction: a meta- analysis. JAMA. 2004;292:362 6. 273. Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol. 2007;49:1517 24. 274. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarc- tion: quantitative review of randomised trials. Lancet. 2006;367:579 88. Erratum in: Lancet. 2006;367:1656. 275. Van t Hof AWJ, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergo- ing primary angioplasty (On-TIME 2): a multicentre, double-blind, ran- domised controlled trial. Lancet. 2008;372:537 46. 276. El Khoury C, Dubien P-Y, Mercier C, et al. Prehospital high-dose tirofi- ban in patients undergoing primary percutaneous intervention: the AGIR- 2 study. Arch Cardiovasc Dis. 2010;103:285 92. 277. De Luca G, Bellandi F, Huber K, et al. Early glycoprotein IIb-IIIa inhibi- tors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient s data meta-analysis. J Thromb Haemost. 2011;9:2361 70. 278. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percu- taneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933 40. 279. Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardio- vasc Interv. 2004;62:186 92. 280. Romagnoli E, Burzotta F, Trani C, et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol. 2005;105:250 5. 281. Iversen A, Galatius S, Jensen JS. The optimal route of administration of the glycoprotein IIb/IIIa receptor antagonist abciximab during percutane- ous coronary intervention: intravenous versus intracoronary. Curr Car- diol Rev. 2008;4:293 9. 282. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoro- nary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv. 2004;61:31 4. 283. W hrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable an- gina undergoing coronary angioplasty. Circulation. 2003;107:1840 3. 284. Bertrand OF, Rod s-Cabau J, Larose E, et al. Intracoronary compared to intravenous abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction un- dergoing transradial primary percutaneous coronary intervention: a two- by-two factorial placebo-controlled randomized study. Am J Cardiol. 2010;105:1520 7. 285. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354 62. 286. Collet J-P, Hulot J-S, Pena A, et al. Cytochrome P450 2C19 polymor- phism in young patients treated with clopidogrel after myocardial infarc- tion: a cohort study. Lancet. 2009;373:309 17. 287. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of- function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916 22. 288. Giusti B, GoriAM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009;103:806 11. 289. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clini- cal alert: approaches to the FDA boxed warning : a report of the Ameri- can College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537 57. 290. Par G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on out- comes of clopidogrel treatment. N Engl J Med. 2010;363:1704 14. 291. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909 17. 292. O Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989 97. 293. AstraZeneca. Brilinta REMS Document. Available at: http://www.fda. gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformation- forPatientsandProviders/UCM264004.pdf. Accessed July 26, 2012. 294. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361: 1045 57. 295. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544 54. 296. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel add- ed to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066 78. 297. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopido- grel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331 7. 298. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238 51. 299. James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or tran- sient ischemic attack. Circulation. 2012;125:2914 21. 300. Verheugt FWA. Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke. Circulation. 2012;125:2821 3. 301. Shimada YJ, Nakra NC, Fox JT, et al. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intrave- nous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2012;109:624 8. 302. Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intra- venous administration of abciximab in patients with ST-segment eleva- tion myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Re- perfusion of ST-Segment Elevation Myocardial Infarction (CICERO) trial. Circulation. 2010;122:2709 17. 303. Thiele H, W hrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet. 2012;379:923 31. 304. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295:1519 30. 305. Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open- label ATOLL trial. Lancet. 2011;378:693 703. 306. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-con- trolled clinical trial. Lancet. 1988;1:545 9. 307. EMERAS (Estudio Multic ntrico Estreptoquinasa Rep blicas de Am rica del Sur) Collaborative Group. Randomised trial of late throm- bolysis in patients with suspected acute myocardial infarction. Lancet. 1993;342:767 72. 308. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349 60. 309. Late Assessment of Thrombolytic Efficacy (LATE) study with al- teplase 6 24 hours after onset of acute myocardial infarction. Lancet. 1993;342:759 66. 310. Rossi P, Bolognese L. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction: Urochinasi per via Sistemica nell Infarto Miocardico (USIM) Collaborative Group. Am J Cardiol. 1991;68:585 92. 311. The I.S.A.M. Study Group. A prospective trial of Intravenous Streptoki- nase in Acute Myocardial infarction (I.S.A.M.): mortality, morbidity, and infarct size at 21 days. N Engl J Med. 1986;314:1465 71. 312. The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation. 1993;87:38 52. 313. Barrab s JA, Figueras J, Moure C, et al. Prognostic value of lead aVR in patients with a first non-ST-segment elevation acute myocardial infarc- tion. Circulation. 2003;108:814 9. 314. Bode C, Smalling RW, Berg G, et al; RAPID II Investigators. Random- ized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, acceler- ated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94:891 8. 315. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plas- minogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lan- cet. 1992;339:753 70. 316. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA. 2001;286:442 9. 317. The Global Use of Strategies to Open Occluded CoronaryArteries (GUS- TO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118 23. 318. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673 82. 319. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716 22. 320. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction:Anglo-Scan- dinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525 30. 321. Bonnefoy E, Godon P, Kirkorian G, et al. Significance of serum troponin I elevation in patients with acute aortic dissection of the ascending aorta. Acta Cardiol. 2005;60:165 70. 322. Langer A, Goodman SG, Topol EJ, et al; LATE Study Investigators. Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. J Am Coll Cardiol. 1996;27:1327 32. 323. Terkelsen CJ, Lassen JF, N rgaard BL, et al. Are we underestimating the full potential of early thrombolytic treatment in patients with acute myocardial infarction? Heart. 2003;89:483 4. 324. The GUSTO Angiographic Investigators. The effects of tissue plasmino- gen activator, streptokinase, or both on coronary-artery patency, ventric- ular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615 22. Erratum in: N Engl J Med. 1994;330:516. 325. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation. 2001;103:2862 6. 326. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol. 1992;19:885 91. 327. Deleted in press. 328. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95:351 6. 329. Martin GV, Sheehan FH, Stadius M, et al. 